Novartis Promotional Sponsored Session - Tackling CVD and healthcare inequalities across the UK through PHM
Inclisiran▼ (Leqvio®) prescribing information and adverse event reporting can be found here:
With a focus on tackling healthcare inequalities and the cardiovascular disease (CVD) burden across the UK, this panel discussion will inform delegates on the current state of play in CVD and introduce the concept of population health management (PHM) as a long-term solution to address these issues. The session will include a case study and key learnings from a GP’s experiences on what has helped them to adopt population health tools to support local PHM delivery and stimulate thinking and discussion.
Discussion will primarily focus on the NHS-Novartis inclisiran▼ (Leqvio®) population health collaboration and learnings from the Greater Manchester case study, and how these can be adopted to realise the potential of PHM and deliver personalised patient care in communities.
This promotional session has been funded by Novartis Pharmaceuticals UK Limited.
The Accelerated Access Collaborative (AAC) has developed the content and delivered this session.
Novartis has certified the associated materials in line with the ABPI Code.
Prescribing information and adverse event reporting can be found here:
Inclisiran is not yet available to prescribe in the UK
130707 June 2021
This session is delivered in partnership with Novartis Pharmaceuticals UK and the Accelerated Access Collaborative.
This session forms part of the System Integration & Collaboration theme, which is sponsored by Novartis Pharmaceuticals UK.